DXCM Stock Analysis: Buy, Sell, or Hold?
DXCM - DexCom, Inc.
$76.35
1.39 (1.85%)
▲
5d:
+5.48%
30d:
+2.11%
90d:
+19.26%
BUY
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Jul 29, 2026
15d
Smart Money Distribution
None View Scanner →
Strength: 9.0/10
Get Alerted When DXCM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: DXCM shows positive signals but monitor for confirmation. Market pricing in 0.9% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: DXCM shows positive signals but monitor for confirmation. Market pricing in 0.9% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$126.82
Based on 11.5% avg growth
INTRINSIC VALUE TODAY
$78.75
3.0% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 24.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: DXCM is currently trading at $76.35, which is considered extended relative to its 30-day fair value range of $69.73 to $75.26. The stock's valuation (Forward PE: 24.8) is in line with its historical norms (24.1). At these levels, the market is pricing in 0.9% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, DXCM is in a downtrend. The price is approaching resistance at $76.01. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: DXCM has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $85.24 (+11.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, DXCM is in a downtrend. The price is approaching resistance at $76.01. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: DXCM has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $85.24 (+11.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$69.73 -
$75.26
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
60.5%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($85.24)
- NEUTRAL: Market pricing in 0.9% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$69.73 -
$75.26
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$67.30
Resistance Level
$76.01
Current Trend
Downtrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
24.81
Wall Street Target
$85.24
(+11.6%)
Revenue Growth (YoY)
15.0%
Earnings Growth (YoY)
92.2%
Profit Margin
19.3%
Valuation Premium vs History
+0.9% premium
PE vs Historical
24.8 vs 24.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.9%
(market-implied from PE analysis)
1-Year Target
$77.04
(+1%)
2-Year Target
$77.73
(+2%)
3-Year Target
$78.43
(+3%)
3-Yr Target (if PE normalizes)
(PE: 25→24)
PE COMPRESSION
$76.19
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 24.8, Growth: 18.9%)
$128.19
(+68%)
Base:
(SPY PE: 21.8, Growth: 18.9%)
$112.54
(+47%)
Bear:
(PE: 18.5, Growth: 18.9%)
$95.66
(+25%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (32x PE), but valuation improves significantly next year (25x PE) as earnings recover.
Trailing PE: 31.75 | Current EPS (TTM): $2.30
Bull Case
$107.84
(+44%)
Analyst growth 34.3%, PE expands to 34.9
Base Case
$98.03
(+31%)
Market implied 34.3%, PE stable at 31.8
Bear Case
$49.65
(-34%)
Severe decline -20.0%, PE contracts to 27.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 13, 2026 5:39 PM ET
Data refreshes hourly during market hours. Next update: 6:39 PM
Data refreshes hourly during market hours. Next update: 6:39 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DXCM showing a specific setup today?
Insider Activity (6 Months)
3
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Michael Jon Brown
SELL
1700 shares
2026-04-15
Ro Khanna
SELL
2026-03-30
Ro Khanna
SELL
2026-03-23
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SYK
Stryker Corporation |
BUY
32 analysts |
$386 | 63 BUY |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$97 | 67 BUY |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$116 | 59 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$239 | 57 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$98 | 62 BUY |
Advanced DXCM Option Strategies
Professional options setups generated by AI based on today's DXCM price and gamma walls.
